Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
The mRNA-1273 vaccine was approved for emergency use in December 2020; trial participants who received placebo were informed of the results and offered vaccination. At the close of the blinded phase of the trial, the vaccine efficacy in preventing Covid-19 illness was 93.2%, and the efficacy against...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2021-11, Vol.385 (19), p.1774-1785 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1785 |
|---|---|
| container_issue | 19 |
| container_start_page | 1774 |
| container_title | The New England journal of medicine |
| container_volume | 385 |
| creator | El Sahly, Hana M Baden, Lindsey R Essink, Brandon Doblecki-Lewis, Susanne Martin, Judith M Anderson, Evan J Campbell, Thomas B Clark, Jesse Jackson, Lisa A Fichtenbaum, Carl J Zervos, Marcus Rankin, Bruce Eder, Frank Feldman, Gregory Kennelly, Christina Han-Conrad, Laurie Levin, Michael Neuzil, Kathleen M Corey, Lawrence Gilbert, Peter Janes, Holly Follmann, Dean Marovich, Mary Polakowski, Laura Mascola, John R Ledgerwood, Julie E Graham, Barney S August, Allison Clouting, Heather Deng, Weiping Han, Shu Leav, Brett Manzo, Deb Pajon, Rolando Schödel, Florian Tomassini, Joanne E Zhou, Honghong Miller, Jacqueline |
| description | The mRNA-1273 vaccine was approved for emergency use in December 2020; trial participants who received placebo were informed of the results and offered vaccination. At the close of the blinded phase of the trial, the vaccine efficacy in preventing Covid-19 illness was 93.2%, and the efficacy against severe disease was 98.2%. No new safety issues were identified. |
| doi_str_mv | 10.1056/NEJMoa2113017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8482810</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2575830635</sourcerecordid><originalsourceid>FETCH-LOGICAL-c583t-1b637f171b36b8c6f947b85790cdac35a04c5e92c4b58789aad2deb1a600f4b13</originalsourceid><addsrcrecordid>eNp10Utr3DAUBWARWjLTJMtui6EEulGjq4clbwITM31OHuQxWyHLcseDbU0su5B_X4VJQicQbbTQp8O9HIQ-AvkKRKQnF_Nf595QAEZA7qEpCMYw5yR9h6aEUIW5zNgEfQhhTeIBnu2jCeNCAKViin7Pq6q2xj4kvkqGlUva64sZBipZcjO7vsG5X2KaLI21decSMyS5bzeNG2rfPf44a-qudGVytTLBHaL3lWmCO3q6D9Ddt_lt_gMvLr__zGcLbIViA4YiZbICCQVLC2XTKuOyUEJmxJbGMmEIt8Jl1PJCKKkyY0paugJMSkjFC2AH6HSbuxmL1pXWdUNvGr3p69b0D9qbWu--dPVK__F_teKKKiAx4MtTQO_vRxcG3dbBuqYxnfNj0FTIOClJmYj08yu69mPfxfWiyhgwUCqNCm-V7X0IvatehgGiH2vSOzVF_-n_DV70cy8RHG9B2wbduXX7RtA_bA6V2Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2593131886</pqid></control><display><type>article</type><title>Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>New England Journal of Medicine</source><creator>El Sahly, Hana M ; Baden, Lindsey R ; Essink, Brandon ; Doblecki-Lewis, Susanne ; Martin, Judith M ; Anderson, Evan J ; Campbell, Thomas B ; Clark, Jesse ; Jackson, Lisa A ; Fichtenbaum, Carl J ; Zervos, Marcus ; Rankin, Bruce ; Eder, Frank ; Feldman, Gregory ; Kennelly, Christina ; Han-Conrad, Laurie ; Levin, Michael ; Neuzil, Kathleen M ; Corey, Lawrence ; Gilbert, Peter ; Janes, Holly ; Follmann, Dean ; Marovich, Mary ; Polakowski, Laura ; Mascola, John R ; Ledgerwood, Julie E ; Graham, Barney S ; August, Allison ; Clouting, Heather ; Deng, Weiping ; Han, Shu ; Leav, Brett ; Manzo, Deb ; Pajon, Rolando ; Schödel, Florian ; Tomassini, Joanne E ; Zhou, Honghong ; Miller, Jacqueline</creator><creatorcontrib>El Sahly, Hana M ; Baden, Lindsey R ; Essink, Brandon ; Doblecki-Lewis, Susanne ; Martin, Judith M ; Anderson, Evan J ; Campbell, Thomas B ; Clark, Jesse ; Jackson, Lisa A ; Fichtenbaum, Carl J ; Zervos, Marcus ; Rankin, Bruce ; Eder, Frank ; Feldman, Gregory ; Kennelly, Christina ; Han-Conrad, Laurie ; Levin, Michael ; Neuzil, Kathleen M ; Corey, Lawrence ; Gilbert, Peter ; Janes, Holly ; Follmann, Dean ; Marovich, Mary ; Polakowski, Laura ; Mascola, John R ; Ledgerwood, Julie E ; Graham, Barney S ; August, Allison ; Clouting, Heather ; Deng, Weiping ; Han, Shu ; Leav, Brett ; Manzo, Deb ; Pajon, Rolando ; Schödel, Florian ; Tomassini, Joanne E ; Zhou, Honghong ; Miller, Jacqueline ; COVE Study Group</creatorcontrib><description>The mRNA-1273 vaccine was approved for emergency use in December 2020; trial participants who received placebo were informed of the results and offered vaccination. At the close of the blinded phase of the trial, the vaccine efficacy in preventing Covid-19 illness was 93.2%, and the efficacy against severe disease was 98.2%. No new safety issues were identified.</description><identifier>ISSN: 0028-4793</identifier><identifier>ISSN: 1533-4406</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa2113017</identifier><identifier>PMID: 34551225</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>2019-nCoV Vaccine mRNA-1273 ; Adolescent ; Adult ; Aged ; Allergies ; Asymptomatic ; Asymptomatic infection ; Clinical trials ; Consent ; Coronavirus ; Coronaviruses ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - adverse effects ; COVID-19 Vaccines - immunology ; Follow-Up Studies ; Humans ; Immunization ; Immunization, Secondary ; Immunogenicity, Vaccine ; Incidence ; Infections ; Infectious Disease ; Infectious diseases ; Injection ; Injections ; Intention to Treat Analysis ; Male ; Middle Aged ; mRNA ; Original ; Patient Acuity ; Placebos ; Population ; Safety ; Severe acute respiratory syndrome coronavirus 2 ; Single-Blind Method ; Statistical analysis ; Treatment Outcome ; Vaccine efficacy ; Vaccines ; Young Adult</subject><ispartof>The New England journal of medicine, 2021-11, Vol.385 (19), p.1774-1785</ispartof><rights>Copyright © 2021 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright © 2021 Massachusetts Medical Society.</rights><rights>Copyright © 2021 Massachusetts Medical Society. All rights reserved. 2021 Massachusetts Medical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c583t-1b637f171b36b8c6f947b85790cdac35a04c5e92c4b58789aad2deb1a600f4b13</citedby><cites>FETCH-LOGICAL-c583t-1b637f171b36b8c6f947b85790cdac35a04c5e92c4b58789aad2deb1a600f4b13</cites><orcidid>0000-0002-2179-2436 ; 0000-0001-5862-6530 ; 0000-0003-0489-0074 ; 0000-0002-1576-4420 ; 0000-0002-1785-0218</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa2113017$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa2113017$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>230,314,776,780,881,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34551225$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>El Sahly, Hana M</creatorcontrib><creatorcontrib>Baden, Lindsey R</creatorcontrib><creatorcontrib>Essink, Brandon</creatorcontrib><creatorcontrib>Doblecki-Lewis, Susanne</creatorcontrib><creatorcontrib>Martin, Judith M</creatorcontrib><creatorcontrib>Anderson, Evan J</creatorcontrib><creatorcontrib>Campbell, Thomas B</creatorcontrib><creatorcontrib>Clark, Jesse</creatorcontrib><creatorcontrib>Jackson, Lisa A</creatorcontrib><creatorcontrib>Fichtenbaum, Carl J</creatorcontrib><creatorcontrib>Zervos, Marcus</creatorcontrib><creatorcontrib>Rankin, Bruce</creatorcontrib><creatorcontrib>Eder, Frank</creatorcontrib><creatorcontrib>Feldman, Gregory</creatorcontrib><creatorcontrib>Kennelly, Christina</creatorcontrib><creatorcontrib>Han-Conrad, Laurie</creatorcontrib><creatorcontrib>Levin, Michael</creatorcontrib><creatorcontrib>Neuzil, Kathleen M</creatorcontrib><creatorcontrib>Corey, Lawrence</creatorcontrib><creatorcontrib>Gilbert, Peter</creatorcontrib><creatorcontrib>Janes, Holly</creatorcontrib><creatorcontrib>Follmann, Dean</creatorcontrib><creatorcontrib>Marovich, Mary</creatorcontrib><creatorcontrib>Polakowski, Laura</creatorcontrib><creatorcontrib>Mascola, John R</creatorcontrib><creatorcontrib>Ledgerwood, Julie E</creatorcontrib><creatorcontrib>Graham, Barney S</creatorcontrib><creatorcontrib>August, Allison</creatorcontrib><creatorcontrib>Clouting, Heather</creatorcontrib><creatorcontrib>Deng, Weiping</creatorcontrib><creatorcontrib>Han, Shu</creatorcontrib><creatorcontrib>Leav, Brett</creatorcontrib><creatorcontrib>Manzo, Deb</creatorcontrib><creatorcontrib>Pajon, Rolando</creatorcontrib><creatorcontrib>Schödel, Florian</creatorcontrib><creatorcontrib>Tomassini, Joanne E</creatorcontrib><creatorcontrib>Zhou, Honghong</creatorcontrib><creatorcontrib>Miller, Jacqueline</creatorcontrib><creatorcontrib>COVE Study Group</creatorcontrib><title>Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>The mRNA-1273 vaccine was approved for emergency use in December 2020; trial participants who received placebo were informed of the results and offered vaccination. At the close of the blinded phase of the trial, the vaccine efficacy in preventing Covid-19 illness was 93.2%, and the efficacy against severe disease was 98.2%. No new safety issues were identified.</description><subject>2019-nCoV Vaccine mRNA-1273</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Allergies</subject><subject>Asymptomatic</subject><subject>Asymptomatic infection</subject><subject>Clinical trials</subject><subject>Consent</subject><subject>Coronavirus</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 vaccines</subject><subject>COVID-19 Vaccines - adverse effects</subject><subject>COVID-19 Vaccines - immunology</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization, Secondary</subject><subject>Immunogenicity, Vaccine</subject><subject>Incidence</subject><subject>Infections</subject><subject>Infectious Disease</subject><subject>Infectious diseases</subject><subject>Injection</subject><subject>Injections</subject><subject>Intention to Treat Analysis</subject><subject>Male</subject><subject>Middle Aged</subject><subject>mRNA</subject><subject>Original</subject><subject>Patient Acuity</subject><subject>Placebos</subject><subject>Population</subject><subject>Safety</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Single-Blind Method</subject><subject>Statistical analysis</subject><subject>Treatment Outcome</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Young Adult</subject><issn>0028-4793</issn><issn>1533-4406</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10Utr3DAUBWARWjLTJMtui6EEulGjq4clbwITM31OHuQxWyHLcseDbU0su5B_X4VJQicQbbTQp8O9HIQ-AvkKRKQnF_Nf595QAEZA7qEpCMYw5yR9h6aEUIW5zNgEfQhhTeIBnu2jCeNCAKViin7Pq6q2xj4kvkqGlUva64sZBipZcjO7vsG5X2KaLI21decSMyS5bzeNG2rfPf44a-qudGVytTLBHaL3lWmCO3q6D9Ddt_lt_gMvLr__zGcLbIViA4YiZbICCQVLC2XTKuOyUEJmxJbGMmEIt8Jl1PJCKKkyY0paugJMSkjFC2AH6HSbuxmL1pXWdUNvGr3p69b0D9qbWu--dPVK__F_teKKKiAx4MtTQO_vRxcG3dbBuqYxnfNj0FTIOClJmYj08yu69mPfxfWiyhgwUCqNCm-V7X0IvatehgGiH2vSOzVF_-n_DV70cy8RHG9B2wbduXX7RtA_bA6V2Q</recordid><startdate>20211104</startdate><enddate>20211104</enddate><creator>El Sahly, Hana M</creator><creator>Baden, Lindsey R</creator><creator>Essink, Brandon</creator><creator>Doblecki-Lewis, Susanne</creator><creator>Martin, Judith M</creator><creator>Anderson, Evan J</creator><creator>Campbell, Thomas B</creator><creator>Clark, Jesse</creator><creator>Jackson, Lisa A</creator><creator>Fichtenbaum, Carl J</creator><creator>Zervos, Marcus</creator><creator>Rankin, Bruce</creator><creator>Eder, Frank</creator><creator>Feldman, Gregory</creator><creator>Kennelly, Christina</creator><creator>Han-Conrad, Laurie</creator><creator>Levin, Michael</creator><creator>Neuzil, Kathleen M</creator><creator>Corey, Lawrence</creator><creator>Gilbert, Peter</creator><creator>Janes, Holly</creator><creator>Follmann, Dean</creator><creator>Marovich, Mary</creator><creator>Polakowski, Laura</creator><creator>Mascola, John R</creator><creator>Ledgerwood, Julie E</creator><creator>Graham, Barney S</creator><creator>August, Allison</creator><creator>Clouting, Heather</creator><creator>Deng, Weiping</creator><creator>Han, Shu</creator><creator>Leav, Brett</creator><creator>Manzo, Deb</creator><creator>Pajon, Rolando</creator><creator>Schödel, Florian</creator><creator>Tomassini, Joanne E</creator><creator>Zhou, Honghong</creator><creator>Miller, Jacqueline</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2179-2436</orcidid><orcidid>https://orcid.org/0000-0001-5862-6530</orcidid><orcidid>https://orcid.org/0000-0003-0489-0074</orcidid><orcidid>https://orcid.org/0000-0002-1576-4420</orcidid><orcidid>https://orcid.org/0000-0002-1785-0218</orcidid></search><sort><creationdate>20211104</creationdate><title>Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase</title><author>El Sahly, Hana M ; Baden, Lindsey R ; Essink, Brandon ; Doblecki-Lewis, Susanne ; Martin, Judith M ; Anderson, Evan J ; Campbell, Thomas B ; Clark, Jesse ; Jackson, Lisa A ; Fichtenbaum, Carl J ; Zervos, Marcus ; Rankin, Bruce ; Eder, Frank ; Feldman, Gregory ; Kennelly, Christina ; Han-Conrad, Laurie ; Levin, Michael ; Neuzil, Kathleen M ; Corey, Lawrence ; Gilbert, Peter ; Janes, Holly ; Follmann, Dean ; Marovich, Mary ; Polakowski, Laura ; Mascola, John R ; Ledgerwood, Julie E ; Graham, Barney S ; August, Allison ; Clouting, Heather ; Deng, Weiping ; Han, Shu ; Leav, Brett ; Manzo, Deb ; Pajon, Rolando ; Schödel, Florian ; Tomassini, Joanne E ; Zhou, Honghong ; Miller, Jacqueline</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c583t-1b637f171b36b8c6f947b85790cdac35a04c5e92c4b58789aad2deb1a600f4b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>2019-nCoV Vaccine mRNA-1273</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Allergies</topic><topic>Asymptomatic</topic><topic>Asymptomatic infection</topic><topic>Clinical trials</topic><topic>Consent</topic><topic>Coronavirus</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 vaccines</topic><topic>COVID-19 Vaccines - adverse effects</topic><topic>COVID-19 Vaccines - immunology</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization, Secondary</topic><topic>Immunogenicity, Vaccine</topic><topic>Incidence</topic><topic>Infections</topic><topic>Infectious Disease</topic><topic>Infectious diseases</topic><topic>Injection</topic><topic>Injections</topic><topic>Intention to Treat Analysis</topic><topic>Male</topic><topic>Middle Aged</topic><topic>mRNA</topic><topic>Original</topic><topic>Patient Acuity</topic><topic>Placebos</topic><topic>Population</topic><topic>Safety</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Single-Blind Method</topic><topic>Statistical analysis</topic><topic>Treatment Outcome</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>El Sahly, Hana M</creatorcontrib><creatorcontrib>Baden, Lindsey R</creatorcontrib><creatorcontrib>Essink, Brandon</creatorcontrib><creatorcontrib>Doblecki-Lewis, Susanne</creatorcontrib><creatorcontrib>Martin, Judith M</creatorcontrib><creatorcontrib>Anderson, Evan J</creatorcontrib><creatorcontrib>Campbell, Thomas B</creatorcontrib><creatorcontrib>Clark, Jesse</creatorcontrib><creatorcontrib>Jackson, Lisa A</creatorcontrib><creatorcontrib>Fichtenbaum, Carl J</creatorcontrib><creatorcontrib>Zervos, Marcus</creatorcontrib><creatorcontrib>Rankin, Bruce</creatorcontrib><creatorcontrib>Eder, Frank</creatorcontrib><creatorcontrib>Feldman, Gregory</creatorcontrib><creatorcontrib>Kennelly, Christina</creatorcontrib><creatorcontrib>Han-Conrad, Laurie</creatorcontrib><creatorcontrib>Levin, Michael</creatorcontrib><creatorcontrib>Neuzil, Kathleen M</creatorcontrib><creatorcontrib>Corey, Lawrence</creatorcontrib><creatorcontrib>Gilbert, Peter</creatorcontrib><creatorcontrib>Janes, Holly</creatorcontrib><creatorcontrib>Follmann, Dean</creatorcontrib><creatorcontrib>Marovich, Mary</creatorcontrib><creatorcontrib>Polakowski, Laura</creatorcontrib><creatorcontrib>Mascola, John R</creatorcontrib><creatorcontrib>Ledgerwood, Julie E</creatorcontrib><creatorcontrib>Graham, Barney S</creatorcontrib><creatorcontrib>August, Allison</creatorcontrib><creatorcontrib>Clouting, Heather</creatorcontrib><creatorcontrib>Deng, Weiping</creatorcontrib><creatorcontrib>Han, Shu</creatorcontrib><creatorcontrib>Leav, Brett</creatorcontrib><creatorcontrib>Manzo, Deb</creatorcontrib><creatorcontrib>Pajon, Rolando</creatorcontrib><creatorcontrib>Schödel, Florian</creatorcontrib><creatorcontrib>Tomassini, Joanne E</creatorcontrib><creatorcontrib>Zhou, Honghong</creatorcontrib><creatorcontrib>Miller, Jacqueline</creatorcontrib><creatorcontrib>COVE Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>El Sahly, Hana M</au><au>Baden, Lindsey R</au><au>Essink, Brandon</au><au>Doblecki-Lewis, Susanne</au><au>Martin, Judith M</au><au>Anderson, Evan J</au><au>Campbell, Thomas B</au><au>Clark, Jesse</au><au>Jackson, Lisa A</au><au>Fichtenbaum, Carl J</au><au>Zervos, Marcus</au><au>Rankin, Bruce</au><au>Eder, Frank</au><au>Feldman, Gregory</au><au>Kennelly, Christina</au><au>Han-Conrad, Laurie</au><au>Levin, Michael</au><au>Neuzil, Kathleen M</au><au>Corey, Lawrence</au><au>Gilbert, Peter</au><au>Janes, Holly</au><au>Follmann, Dean</au><au>Marovich, Mary</au><au>Polakowski, Laura</au><au>Mascola, John R</au><au>Ledgerwood, Julie E</au><au>Graham, Barney S</au><au>August, Allison</au><au>Clouting, Heather</au><au>Deng, Weiping</au><au>Han, Shu</au><au>Leav, Brett</au><au>Manzo, Deb</au><au>Pajon, Rolando</au><au>Schödel, Florian</au><au>Tomassini, Joanne E</au><au>Zhou, Honghong</au><au>Miller, Jacqueline</au><aucorp>COVE Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2021-11-04</date><risdate>2021</risdate><volume>385</volume><issue>19</issue><spage>1774</spage><epage>1785</epage><pages>1774-1785</pages><issn>0028-4793</issn><issn>1533-4406</issn><eissn>1533-4406</eissn><abstract>The mRNA-1273 vaccine was approved for emergency use in December 2020; trial participants who received placebo were informed of the results and offered vaccination. At the close of the blinded phase of the trial, the vaccine efficacy in preventing Covid-19 illness was 93.2%, and the efficacy against severe disease was 98.2%. No new safety issues were identified.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>34551225</pmid><doi>10.1056/NEJMoa2113017</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-2179-2436</orcidid><orcidid>https://orcid.org/0000-0001-5862-6530</orcidid><orcidid>https://orcid.org/0000-0003-0489-0074</orcidid><orcidid>https://orcid.org/0000-0002-1576-4420</orcidid><orcidid>https://orcid.org/0000-0002-1785-0218</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2021-11, Vol.385 (19), p.1774-1785 |
| issn | 0028-4793 1533-4406 1533-4406 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8482810 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; New England Journal of Medicine |
| subjects | 2019-nCoV Vaccine mRNA-1273 Adolescent Adult Aged Allergies Asymptomatic Asymptomatic infection Clinical trials Consent Coronavirus Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - adverse effects COVID-19 Vaccines - immunology Follow-Up Studies Humans Immunization Immunization, Secondary Immunogenicity, Vaccine Incidence Infections Infectious Disease Infectious diseases Injection Injections Intention to Treat Analysis Male Middle Aged mRNA Original Patient Acuity Placebos Population Safety Severe acute respiratory syndrome coronavirus 2 Single-Blind Method Statistical analysis Treatment Outcome Vaccine efficacy Vaccines Young Adult |
| title | Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T16%3A21%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20the%20mRNA-1273%20SARS-CoV-2%20Vaccine%20at%20Completion%20of%20Blinded%20Phase&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=El%20Sahly,%20Hana%20M&rft.aucorp=COVE%20Study%20Group&rft.date=2021-11-04&rft.volume=385&rft.issue=19&rft.spage=1774&rft.epage=1785&rft.pages=1774-1785&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa2113017&rft_dat=%3Cproquest_pubme%3E2575830635%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2593131886&rft_id=info:pmid/34551225&rfr_iscdi=true |